Triple-negative breast cancer (TNBC) is particularly difficult to target because it does not or at low levels at best express estrogen, progesterone, or Her2/Neu receptors—signaling pathways involved at least in part for many current FDA-approved breast cancer therapeutics. Here, ERBB2 is linked to triple-negative breast carcinoma.